Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
0.8000
Dollar change
-0.0099
Percentage change
-1.22
%
Index- P/E- EPS (ttm)-0.59 Insider Own24.56% Shs Outstand41.25M Perf Week7.02%
Market Cap33.18M Forward P/E- EPS next Y-0.33 Insider Trans0.00% Shs Float31.29M Perf Month20.66%
Income-23.95M PEG- EPS next Q-0.03 Inst Own2.23% Short Float0.51% Perf Quarter29.55%
Sales0.36M P/S92.18 EPS this Y- Inst Trans-40.36% Short Ratio1.54 Perf Half Y25.89%
Book/sh0.11 P/B7.58 EPS next Y- ROA-47.19% Short Interest0.16M Perf Year-19.20%
Cash/sh0.75 P/C1.07 EPS next 5Y- ROE-173.61% 52W Range0.43 - 1.08 Perf YTD38.05%
Dividend Est.- P/FCF- EPS past 5Y20.93% ROI-70.02% 52W High-25.93% Beta1.45
Dividend TTM- Quick Ratio7.12 Sales past 5Y-25.35% Gross Margin14.57% 52W Low85.57% ATR (14)0.07
Dividend Ex-Date- Current Ratio7.12 EPS Y/Y TTM42.37% Oper. Margin-6788.24% RSI (14)58.76 Volatility7.19% 10.11%
Employees134 Debt/Eq6.92 Sales Y/Y TTM10.53% Profit Margin-6708.40% Recom3.00 Target Price3.00
Option/ShortYes / Yes LT Debt/Eq6.77 EPS Q/Q51.70% Payout- Rel Volume0.29 Prev Close0.81
Sales Surprise- EPS Surprise- Sales Q/Q5150.00% Earnings- Avg Volume104.36K Price0.80
SMA206.22% SMA5020.51% SMA20018.92% Trades Volume29,894 Change-1.22%
Feb-28-24 07:00AM
Feb-12-24 05:20PM
Jan-23-24 02:00AM
Jan-08-24 07:00AM
Dec-21-23 07:00AM
07:29PM Loading…
Nov-13-23 07:29PM
Aug-16-23 07:00AM
Jul-13-23 02:00AM
Jul-12-23 11:17AM
Jul-11-23 02:00AM
Apr-27-23 07:00AM
Mar-13-23 08:00AM
Dec-22-22 07:00AM
Dec-15-22 04:05PM
Nov-10-22 07:00AM
08:00AM Loading…
Oct-31-22 08:00AM
Sep-29-22 07:00AM
Sep-06-22 07:00AM
Apr-07-22 07:00AM
Apr-01-22 07:00AM
Mar-31-22 07:00AM
Mar-28-22 07:00AM
Mar-23-22 07:00AM
Mar-17-22 07:00AM
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.